Docetaxel and epirubicin salvage regimen in relapsed anthracycline- sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy

Investigational New Drugs

Volumn 27, Issue 1, 2009, Pages 67-73

  Seo, Jae Hong ^a   Sung, Hwa Jung ^a   Park, Kyong Hwa ^a   Choi, In Keun ^a   Oh, Sang Cheul ^a   Shin, Sang Won ^a   Kim, Yeul Hong ^a   Kim, Jun Suk ^b   Kim, Ae Ree ^a   Lee, Jae Bok ^a   Koo, Bum Hwan ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Anthracycline; Docetaxel; Epirubicin; Metastatic breast cancer; Sensitive

Indexed keywords

DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUCOGEN; METOCLOPRAMIDE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; SALVAGE THERAPY; SURVIVAL; TUMOR RECURRENCE;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS;

EID: 62749130644     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9151-2     Document Type: Article

References (22)

1. EA Perez 1999 Current management of metastatic breast cancer Semin Oncol 26 1 10 (Pubitemid 29411428)
2. PA Greenberg GN Hortobagyi TL Smith LD Ziegler DK Frye AU Buzdar 1996 Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 2197 2205 (Pubitemid 26264869)
3. R Fossati C Confalonieri V Torri E Ghislandi A Penna V Pistotti 1998 Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women J Clin Oncol 16 3439 3460 (Pubitemid 28481644)
4. Early Breast Cancer Trialists' Collaborative Group 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930 942 DOI:doi:10.1016/S0140-6736(98)03301-7
5. C Pacilio A Morabito F Nuzzo A Gravina V Labonia G Landi 2006 Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial Br J Cancer 94 1233 1236 DOI:doi:10.1038/sj.bjc.6603096
6. HT Mouridsen 1992 Systemic therapy of advanced breast cancer Drugs 44 Suppl 4 17 28 (Pubitemid 23025991)
7. French Epirubicin Study Group 1988 A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin J Clin Oncol 6 679 688
8. Italian Multicentre Breast Study with Epirubicin 1988 Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial J Clin Oncol 6 976 982
9. G Bonadonna L Gianni A Santoro V Bonfante P Bidoli P Casali 1993 Drugs ten years later: epirubicin Ann Oncol 4 359 369 (Pubitemid 23193100)
10. JE Cortes R Pazdur 1995 Docetaxel J Clin Oncol 13 2643 2655
11. V Valero 1997 Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy Semin Oncol 24 S13 S18
12. AT van Oosterom D Schrijvers D Schriivers 1995 Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience Anticancer Drugs 6 356 368 DOI:doi:10.1097/00001813-199506000-00002
13. DR Budman A Calabro 2002 In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines Breast Cancer Res Treat 74 41 46 DOI:doi:10.1023/A:1016070230538
14. V Valero GN Hortobagyi 2003 Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol 21 959 962 DOI:doi:10.1200/JCO.2003.11.071
15. T Gamucci AM D'Ottavio E Magnolfi M Barduagni A Vaccaro I Sperduti 2007 Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer Br J Cancer 97 1040 1045 DOI:doi:10.1038/sj.bjc.6603982
16. JD Hainsworth DA Yardley DR Spigel AA Meluch D Rinaldi FM Schnell 2006 Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial Cancer Invest 17 469 473 DOI:doi:10.1080/07357900600814060
17. S Morales A Lorenzo M Ramos P Ballesteros M Mendez C Almanza 2004 Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study Cancer Chemother Pharmacol 53 75 81 (Pubitemid 38161192)
18. E Salminen J Korpela M Varpula R Asola P Varjo S Pyrhonen 2002 Epirubicin/docetaxel regimen in progressive breast cancer-a phase II study Anticancer Drugs 13 925 929 DOI:doi:10.1097/00001813-200210000-00004
19. A Milla-Santos L Milla L Rallo V Solano 2001 High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer Am J Clin Oncol 24 138 142 DOI:doi:10.1097/00000421- 200104000-00008
20. A Fabi P Papaldo MS Pino G Ferretti P Carlini U Pacetti 2004 Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study Anticancer Res 24 1963 1967 (Pubitemid 38954618)
21. A Polyzos N Tsavaris C Kosmas H Gogas M Vadiaka C Markopoulos 2003 Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer Anticancer Res 23 2917 2923 (Pubitemid 36969835)
22. SA Im SB Kim MH Lee YH Im KH Lee HS Song 2005 Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor Oncol Rep 14 481 487